Wire · opportunities
Meet Motivista: Click Therapeutics debuts first-of-its-kind schizophrenia digital therapeutic
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 5 October 2026 · Fusion42 review
Click Therapeutics secured FDA 510(k) clearance for Motivista, the first prescription digital therapeutic specifically targeting negative symptoms of schizophrenia, and is preparing a state-by-state U.S. commercial launch focused on Medicaid coverage.
This Wire brief sits within Fusion42's coverage of Digital Health, and 2 sources have reported it between 5 Oct 2026 and 6 Oct 2026.
◆ ◆ The Wire takeaway
You now have a digital therapeutic approved for a neglected schizophrenia symptom set but must focus on state Medicaid negotiations to access patients. Launch efforts will pivot sharply to coverage wins over broad marketing.
◆ Coverage
2 sources · first reported 5 Oct 2026 · latest 6 Oct 2026
◆ Related on Wire
◆ Topics